Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

191 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Editorial overview: Use of PK-PD for antibacterial drug development: decreasing risk and paths forward for resistant pathogens.
Bhavnani SM, Rex JH. Bhavnani SM, et al. Among authors: rex jh. Curr Opin Pharmacol. 2017 Oct;36:viii-xii. doi: 10.1016/j.coph.2017.11.008. Curr Opin Pharmacol. 2017. PMID: 29246371 No abstract available.
Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.
Hope W, Drusano GL, Rex JH. Hope W, et al. Among authors: rex jh. J Antimicrob Chemother. 2016 Nov;71(11):3008-3019. doi: 10.1093/jac/dkw298. Epub 2016 Aug 5. J Antimicrob Chemother. 2016. PMID: 27494925 Review.
The challenge of antimicrobial resistance: new regulatory tools to support product development.
Tomayko JF, Rex JH, Tenero DM, Goldberger M, Eisenstein BI. Tomayko JF, et al. Among authors: rex jh. Clin Pharmacol Ther. 2014 Aug;96(2):166-8. doi: 10.1038/clpt.2014.107. Epub 2014 May 13. Clin Pharmacol Ther. 2014. PMID: 24823890 Review.
Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Talbot GH, Das A, Cush S, Dane A, Wible M, Echols R, Torres A, Cammarata S, Rex JH, Powers JH, Fleming T, Loutit J, Hoffmann S; Foundation for the National Institutes of Health Biomarkers Consortium HABP/VABP Project Team. Talbot GH, et al. Among authors: rex jh. J Infect Dis. 2019 Apr 19;219(10):1536-1544. doi: 10.1093/infdis/jiy578. J Infect Dis. 2019. PMID: 30649434 Free PMC article.
Reply to Paul and Leibovici.
Boucher HW, Ambrose PG, Chambers HF, Ebright RH, Jezek A, Murray BE, Ostrowsky B, Rex JH. Boucher HW, et al. Among authors: rex jh. J Infect Dis. 2018 Jan 17;217(3):509-510. doi: 10.1093/infdis/jix537. J Infect Dis. 2018. PMID: 29240925 No abstract available.
Analysis of the clinical antibacterial and antituberculosis pipeline.
Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, Moja L, Paul M, Paulin S, Rex JH, Silver LL, Spigelman M, Thwaites GE, Paccaud JP, Harbarth S. Theuretzbacher U, et al. Among authors: rex jh. Lancet Infect Dis. 2019 Feb;19(2):e40-e50. doi: 10.1016/S1473-3099(18)30513-9. Epub 2018 Oct 15. Lancet Infect Dis. 2019. PMID: 30337260
Accelerating global innovation to address antibacterial resistance: introducing CARB-X.
Outterson K, Rex JH, Jinks T, Jackson P, Hallinan J, Karp S, Hung DT, Franceschi F, Merkeley T, Houchens C, Dixon DM, Kurilla MG, Aurigemma R, Larsen J. Outterson K, et al. Among authors: rex jh. Nat Rev Drug Discov. 2016 Sep;15(9):589-590. doi: 10.1038/nrd.2016.155. Epub 2016 Jul 29. Nat Rev Drug Discov. 2016. PMID: 27469032
To the G20: incentivising antibacterial research and development.
Årdal C, Baraldi E, Ciabuschi F, Outterson K, Rex JH, Piddock LJV, Findlay D; DRIVE-AB Steering Committee. Årdal C, et al. Among authors: rex jh. Lancet Infect Dis. 2017 Aug;17(8):799-801. doi: 10.1016/S1473-3099(17)30404-8. Epub 2017 Jul 7. Lancet Infect Dis. 2017. PMID: 28689703 No abstract available.
Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
Towse A, Hoyle CK, Goodall J, Hirsch M, Mestre-Ferrandiz J, Rex JH. Towse A, et al. Among authors: rex jh. Health Policy. 2017 Oct;121(10):1025-1030. doi: 10.1016/j.healthpol.2017.07.011. Epub 2017 Aug 5. Health Policy. 2017. PMID: 28888660
191 results
Jump to page